Accueil   Diary - News   All news ENYO Pharma strengthens its arsenal of hepatitis B potential therapies

ENYO Pharma strengthens its arsenal of hepatitis B potential therapies

ENYO Pharma, a biopharmaceutical company focused on developing treatments for acute and chronic viral infections, is announcing that it has obtained a license to a key patent enabling it to use agonists of the farnesoid X receptor (FXR) as hepatitis B treatments.

 


This nuclear receptor, also known as a bile acid receptor, acts via several metabolic pathways and in particular by controlling the fate of bile acids in the liver and intestine. It also influences the insulin sensitivity of these tissues where it is highly expressed.

 

Read the press release